Contact Us Advertise Events
The Microbiome Business & Science Briefing
Microbi meTimes
Reporting on The Latest Microbiome Business & Scientific Developments
  • Research
  • Clinical & Manufacturing
  • Finance
  • Gastrointestinal
  • GMO & Synbio
  • Gut-Brain Axis
  • Infectious Disease & AMR
  • Oncology
  • Biotics and Supplements
  • Regulatory & Policy
  • Skin Health
  • Women’s Health
  • TRENDING
    Gut microbiome activity linked to exceptional longevity may support healthier aging• City of Hope researchers harness the microbiome to prevent deadly bloodstream infections• LBP-AIEC01: An Engineered Phage Therapy Aimed at a Bacterial Driver of Crohn’s Disease• Neobe Raises $6.8 Million to Break Down the Barriers That Stop Cancer Treatments From Working• MIT engineers create nanoparticles for delivering personalized cancer vaccines• MRM Health and Biocodex Establish Strategic Partnership to Strengthen Future Commercial Supply Capabilities for CORAL®-Based Medicines• Gut microbiome activity linked to exceptional longevity may support healthier aging• City of Hope researchers harness the microbiome to prevent deadly bloodstream infections• LBP-AIEC01: An Engineered Phage Therapy Aimed at a Bacterial Driver of Crohn’s Disease• Neobe Raises $6.8 Million to Break Down the Barriers That Stop Cancer Treatments From Working• MIT engineers create nanoparticles for delivering personalized cancer vaccines• MRM Health and Biocodex Establish Strategic Partnership to Strengthen Future Commercial Supply Capabilities for CORAL®-Based Medicines•
    Editor's Choice /Pharma & Human Health
    Editor's Choice

    Exclusive Interview with Ken Blount, VP Microbiome Research at Ferring Pharmaceuticals

    BY Microbiome Times · DEC 22, 2022 · 1 MIN READ
    in X ✉

    Microbiome Times
    Related Coverage
    Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment
    Editor's Choice

    Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment

    SEP 28, 2026
    A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation
    Editor's Choice

    A pioneering gut bacterium passes Europe’s food-safety review under the EU Novel Food Regulation

    SEP 1, 2026
    Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?
    Editor's Choice

    Stanford’s AI Designed Bacteriophages: Ushering in the Next Phase in IP Strategy for Phage Companies?

    AUG 10, 2026

    Sign up to our free newsletter

    The science, the funding, and the regulation — in your inbox.

    Most Read This Week

    • 1
      Gut microbiome activity linked to exceptional longevity may support healthier aging
    • 2
      Evvy Raises $40M Series B to Scale AI-Powered Precision Diagnostics & Care Platform for Women’s Health
    • 3
      THE ROLE OF BIOFILMS: An Interview with Scioto Biosciences
    • 4
      BiomX Enters Collaboration with Johnson & Johnson Innovation for Discovery of Microbiome-based Biomarkers for IBD
    • 5
      Vedanta Biosciences Receives Award from the Crohn’s & Colitis Foundation to Advance a Microbiome-Derived Therapeutic Program for Interception and Treatment of Inflammatory Bowel Disease

    NEW WHITEPAPER: ORAL DELIVERY OF LIVE BIOTHERAPEUTIC PRODUCTS:

    Microbiome Times Magazine

    Reporting on The Latest Microbiome Business & Scientific Developments

    Sections
    • Pharma & Human Health
    • Finance
    • Research
    • Editor's Choice
    Company
    • Issue Archive
    Business
    • Advertise
    Stay Connected
    • LinkedIn
    • Contact
    © 2026 Microbiome Times Magazine
    Microbiome Times Forum USA

    Meet Your Next Collaborator

    San Francisco  •  October 21–22, 2026

    400+ biotech leaders, VCs and researchers gather for two days of partnering and dealmaking in the microbiome space. Free to attend for start-ups, academic innovators, investors and healthcare organisations.

    View the Program Register Free →